Intellia Therapeutics (NTLA) Non-Current Assets (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Non-Current Assets data on file, last reported at $292.3 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 32.76% year-over-year to $292.3 million in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 28.13% decrease from a year earlier, with the FY2025 full-year figure at $314.4 million, down 42.95% from the prior year.
• Non-Current Assets for Q1 2026 stood at $292.3 million, down from $314.4 million in the prior quarter.
• Over the last five years, Non-Current Assets for NTLA reached as high as $551.2 million in Q4 2024 and fell as low as $215.0 million in Q2 2022.
• Historically, Non-Current Assets has averaged $363.1 million across 5 years, with a median of $349.9 million in 2023.
• On a YoY basis, Non-Current Assets climbed as much as 182.73% in 2022 and fell as far as 56.65% in 2022.
• Year by year, Non-Current Assets stood at $303.3 million in 2022, then decreased by 0.22% to $302.6 million in 2023, then jumped by 82.11% to $551.2 million in 2024, then tumbled by 42.95% to $314.4 million in 2025, then retreated by 7.02% to $292.3 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $292.3 million in Q1 2026, $314.4 million in Q4 2025, and $343.3 million in Q3 2025.